After-Hours Earnings Report for August 15, 2024 : AMAT, BABA, AMCR, COHR, GLOB, HRB, ALVO, RNW, SGML, DESP
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 15 2024
0mins
Should l Buy GLOB?
Source: NASDAQ.COM
Earnings Reports Overview: Several companies, including Applied Materials, Alibaba, and Amcor, are set to report earnings with varying forecasts; AMAT is expected to see a 5.79% increase in EPS, while BABA anticipates a 24.29% decrease compared to last year.
Industry Comparisons: Most companies are projected to outperform their industry averages in terms of Price to Earnings ratios, indicating potential for higher earnings growth relative to competitors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLOB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLOB
Wall Street analysts forecast GLOB stock price to rise
13 Analyst Rating
5 Buy
8 Hold
0 Sell
Moderate Buy
Current: 43.080
Low
61.00
Averages
76.36
High
100.00
Current: 43.080
Low
61.00
Averages
76.36
High
100.00
About GLOB
Globant S.A. is a digitally native technology services company. The Company’s principal operating subsidiary is based in Buenos Aires, Argentina. During the year ended December 31, 2015, 83.7% of its revenues were generated by clients in North America, 11.0% in Latin America and Asia, and 5.3% in Europe. It builds digital journeys, which consists of different software products, including mobile apps, Web apps, sensors and other software and hardware appliances that work orchestrated by a backend that uses big data and fast data to create a understanding of each consumer and how to act upon each scenario. The Company delivers digital journeys with a comprehensive approach that includes Stay Relevant, which helps its customers stay fit for the future of their industries; Discover, which think and conceive specific digital journeys for each customer; Build, which creates each digital journey leveraging the work of its Studios, its services over platforms and its agile pods methodologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Globant and PharmaMar Collaborate to Accelerate Cancer Drug Discovery
- AI System Enhances R&D Efficiency: The multi-agent AI system developed through the collaboration between Globant and PharmaMar achieves over 90% accuracy in complex data retrieval, reducing the time to select cancer drug candidates to one-fifteenth of the previous duration, significantly enhancing R&D efficiency.
- Massive Data Analysis Capability: The platform can analyze vast amounts of scientific, regulatory, and clinical data, assisting PharmaMar in making faster decisions within its R&D ecosystem and enabling continuous self-improvement workflows.
- Prioritization and Literature Review: The system reviews over 4,500 research documents to prioritize the 10 most promising treatment-indication combinations out of 8,000 possibilities, completing what would have taken months of work in a fraction of the time.
- Promotion of Digital Innovation Culture: This collaboration not only accelerates drug discovery speed and efficiency but also strengthens PharmaMar's ability to reuse institutional knowledge, fostering a culture of digital innovation within its teams.
See More
Globant and PharmaMar Collaborate to Accelerate Cancer Drug Discovery
- Multi-Agent AI System: The collaboration between Globant and PharmaMar has launched a multi-agent AI framework that achieves over 90% accuracy in complex data retrieval and reduces insight time by up to 15-fold, significantly accelerating the selection of cancer drug candidates.
- Efficient Data Processing: This system analyzes over 4,500 research documents to prioritize the 10 most viable treatment combinations out of 8,000 possibilities, a task that would have taken months for human researchers, now completed in seconds, greatly enhancing R&D efficiency.
- Innovation Culture Promotion: The partnership not only strengthens PharmaMar's ability to reuse institutional knowledge but also fosters a culture of digital innovation across teams, with plans to extend capabilities to hypothesis generation, real-time compliance checks, and automated scientific reporting content creation.
- Precision Drug Discovery: By integrating Globant's AI technologies, PharmaMar can process thousands of documents in seconds, simulate scenarios, and focus research efforts on areas with the highest potential, thereby offering greater hope for patient treatments.
See More
Globant Files 2025 Annual Report with SEC
- Annual Report Submission: Globant S.A. filed its 2025 Annual Report with the SEC on February 27, 2026, demonstrating the company's commitment to transparency and regulatory compliance.
- Financial Information Access: Shareholders can access the 2025 Annual Report via the company's or SEC's website and request free copies of the complete audited financial statements, reflecting the company's dedication to shareholder service.
- Global Business Presence: With over 28,700 employees across more than 30 countries, Globant serves prominent companies like Google, Electronic Arts, and Santander, showcasing its extensive influence in the digital technology services sector.
- Industry Recognition: The company was named a Worldwide Leader in CX Improvement by the IDC MarketScape report and featured as a business case study at Harvard, MIT, and Stanford, further solidifying its industry position.
See More
Globant Files 2025 Annual Report with SEC
- Annual Report Submission: On February 27, 2026, Globant S.A. filed its 2025 Annual Report with the SEC, demonstrating the company's commitment to transparency and compliance, which is expected to enhance investor confidence.
- Financial Information Access: Shareholders can request a hard copy of the complete audited financial statements, which not only improves information accessibility but also reflects the company's dedication to shareholder rights.
- Global Business Presence: With over 28,700 employees across more than 30 countries, Globant serves major clients like Google, Electronic Arts, and Santander, showcasing its extensive influence in the digital and AI sectors.
- Industry Recognition: The company was named a Worldwide Leader in CX Improvement by IDC MarketScape and featured as a business case study at Harvard, MIT, and Stanford, further solidifying its leadership position in the industry.
See More
Globant (GLOB) Q4 2025 Earnings Call Transcript
See More
Globant to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Globant is set to release its Q4 earnings on February 26 after market close, with a consensus EPS estimate of $1.54, reflecting a 12% year-over-year decline, which may negatively impact investor sentiment.
- Revenue Expectations Decline: The anticipated revenue for Q4 is $605.47 million, down 5.8% year-over-year, indicating challenges the company faces in the current economic environment that could affect future growth strategies.
- Historical Performance Review: Over the past two years, Globant has beaten EPS estimates 63% of the time and revenue estimates 75% of the time, demonstrating a degree of stability in financial performance, although recent downgrades may affect investor expectations.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates and two downward revisions, while revenue estimates saw two upward revisions and one downward, indicating a divergence in market perceptions of the company's future performance.
See More
Globant and PharmaMar Collaborate to Accelerate Cancer Drug Discovery
- AI System Enhances R&D Efficiency: The multi-agent AI system developed through the collaboration between Globant and PharmaMar achieves over 90% accuracy in complex data retrieval, reducing the time to select cancer drug candidates to one-fifteenth of the previous duration, significantly enhancing R&D efficiency.
- Massive Data Analysis Capability: The platform can analyze vast amounts of scientific, regulatory, and clinical data, assisting PharmaMar in making faster decisions within its R&D ecosystem and enabling continuous self-improvement workflows.
- Prioritization and Literature Review: The system reviews over 4,500 research documents to prioritize the 10 most promising treatment-indication combinations out of 8,000 possibilities, completing what would have taken months of work in a fraction of the time.
- Promotion of Digital Innovation Culture: This collaboration not only accelerates drug discovery speed and efficiency but also strengthens PharmaMar's ability to reuse institutional knowledge, fostering a culture of digital innovation within its teams.
See More
Globant and PharmaMar Collaborate to Accelerate Cancer Drug Discovery
- Multi-Agent AI System: The collaboration between Globant and PharmaMar has launched a multi-agent AI framework that achieves over 90% accuracy in complex data retrieval and reduces insight time by up to 15-fold, significantly accelerating the selection of cancer drug candidates.
- Efficient Data Processing: This system analyzes over 4,500 research documents to prioritize the 10 most viable treatment combinations out of 8,000 possibilities, a task that would have taken months for human researchers, now completed in seconds, greatly enhancing R&D efficiency.
- Innovation Culture Promotion: The partnership not only strengthens PharmaMar's ability to reuse institutional knowledge but also fosters a culture of digital innovation across teams, with plans to extend capabilities to hypothesis generation, real-time compliance checks, and automated scientific reporting content creation.
- Precision Drug Discovery: By integrating Globant's AI technologies, PharmaMar can process thousands of documents in seconds, simulate scenarios, and focus research efforts on areas with the highest potential, thereby offering greater hope for patient treatments.
See More
Globant Files 2025 Annual Report with SEC
- Annual Report Submission: Globant S.A. filed its 2025 Annual Report with the SEC on February 27, 2026, demonstrating the company's commitment to transparency and regulatory compliance.
- Financial Information Access: Shareholders can access the 2025 Annual Report via the company's or SEC's website and request free copies of the complete audited financial statements, reflecting the company's dedication to shareholder service.
- Global Business Presence: With over 28,700 employees across more than 30 countries, Globant serves prominent companies like Google, Electronic Arts, and Santander, showcasing its extensive influence in the digital technology services sector.
- Industry Recognition: The company was named a Worldwide Leader in CX Improvement by the IDC MarketScape report and featured as a business case study at Harvard, MIT, and Stanford, further solidifying its industry position.
See More
Globant Files 2025 Annual Report with SEC
- Annual Report Submission: On February 27, 2026, Globant S.A. filed its 2025 Annual Report with the SEC, demonstrating the company's commitment to transparency and compliance, which is expected to enhance investor confidence.
- Financial Information Access: Shareholders can request a hard copy of the complete audited financial statements, which not only improves information accessibility but also reflects the company's dedication to shareholder rights.
- Global Business Presence: With over 28,700 employees across more than 30 countries, Globant serves major clients like Google, Electronic Arts, and Santander, showcasing its extensive influence in the digital and AI sectors.
- Industry Recognition: The company was named a Worldwide Leader in CX Improvement by IDC MarketScape and featured as a business case study at Harvard, MIT, and Stanford, further solidifying its leadership position in the industry.
See More
Globant (GLOB) Q4 2025 Earnings Call Transcript
See More
Globant to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Globant is set to release its Q4 earnings on February 26 after market close, with a consensus EPS estimate of $1.54, reflecting a 12% year-over-year decline, which may negatively impact investor sentiment.
- Revenue Expectations Decline: The anticipated revenue for Q4 is $605.47 million, down 5.8% year-over-year, indicating challenges the company faces in the current economic environment that could affect future growth strategies.
- Historical Performance Review: Over the past two years, Globant has beaten EPS estimates 63% of the time and revenue estimates 75% of the time, demonstrating a degree of stability in financial performance, although recent downgrades may affect investor expectations.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates and two downward revisions, while revenue estimates saw two upward revisions and one downward, indicating a divergence in market perceptions of the company's future performance.
See More
